Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
Article and Video CATEGORIES
Clinical Care Options 2018 - Measurable Residual Disease in Acute Lymphoblastic Leukemia
dbrock
CCO 2018 - MRD in ALL
Image
GRACE has partnered with Clinical Care Options (CCO) Oncology, to share with our community a series of educational videos regarding Measurable Residual Disease (MRD) in acute lymphocytic leukemia (ALL).
We are thrilled to share with you video discussions with the following panel:
- ~Elias Jabbour, MD, Associate Professor Department of Leukemia at the University of Texas MD Anderson Cancer Center in Houston, Texas
- ~Joseph D. Khoury, MD, Professor, Department of Hematology at the University of Texas MD Anderson Cancer Center in Houston, Texas
- ~Aaron C. Logan, MD, Ph.D., Associate Professor Division of Hematology and Blood and Marrow Transplantation at the University of California, San Francisco
In this video series, the doctors discuss MRD in ALL. Topics include:
Measurable Residual Disease - What Can Physicians Do with MRD Information
Measurable Residual Disease - What Does it Mean to be MRD Positive
Measurable Residual Disease - What is MRD and Why is it Important
Measurable Residual Disease - What Tests Used, How do They Work, and Which is Best for the Patient
Measurable Residual Disease - When Should they Test MRD and How do they get MRD from Patients
For more information about this video program with CCO - please visit https://www.clinicaloptions.com/oncology/programs/mrd-in-all/on-demand-….
Video Language
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Image
Article
Tell your story and help us help others! Apply online now for this paid opportunity. This program gives a voice to those who have experience in participating in a clinical trial for a cancer diagnosis. Your voice helps to educate and advocate for others who are in or who may be considering a clinical trial. We want to hear from you!
Image
Video
The Foro de Pacientes de Terapias Dirigidas de Cáncer de Pulmón presentado el 9 de agosto de 2025 has now ended.
¡Los vídeos están disponibles BAJO DEMANDA!
Las versiones completas sin editar del Foro de Pacientes de Terapias Dirigidas de Cáncer de Pulmón de agosto de 2025 ya están disponibles BAJO DEMANDA. Estos temas se editarán y se ofrecerán en forma de vídeos más cortos en las próximas semanas.
Image
Article
Da click aquí para más información y para registrarte ahora
Online Community
Dr. Singhi's reprise on appropriate treatment, "Right patient, right time, right team".
While Dr. Ryckman described radiation oncology as "the perfect blend of nerd skills and empathy".
I hope any...
My understanding of ADCs is very basic. I plan to study Dr. Rous’ discussion to broaden that understanding.
An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:
- The antibody, which serves as the “horse,” specifically targets a protein found on cancer...
Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...
The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)
There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...
Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.
The...
A Brief Tornado. I love the analogy Dr. Antonoff gave us to describe her presentation. I felt it earlier too and am looking forward to going back for deeper dive.